Thanks to @Young_matt_teen for the raid! Good turnout today, 10 ccv until the god raid. Wish I coulda popped off in ranked as a response but I barely held 1900 lol. Its super different midphase. Will keep trying for 2k. Prophet if ur seeing this ggs man hope to play you more

$TRAW Traws defers midphase flu study after negative regulatory review -Traws’ cash runway extends into the first quarter of next year fiercebiotech.com/biotech/tr…

Biogen advances Alzheimer’s tau program despite midphase miss fiercebiotech.com/biotech/bi…

@bcherny codex keep working for hours and competes task end to end while claude even after saying to complete all the phases codes for 15 min then stops in midphase to ask to continue next phases

Amid M&A buzz, Inhibrx's OX40-Keytruda combo shows promise in early look at midphase data fiercebiotech.com/biotech/ox…

Bayer buys Perfuse in $2.4B deal for midphase eye disease prospect fiercebiotech.com/biotech/ba…

Biogen’s litifilimab sparkles in midphase lupus trial! $BIIB #pharma #lupus fiercebiotech.com/biotech/bi…

For my "physics engine" I will do a "midphase" where the <=32 points of a softbody will be divided into 6 regions of its local BB. 32 maps to an uint, and 6 regions can have 5 bits each (5*6=30). The dot produce is used to find the closest region. :3c

it’s not a big difference and is mostly just rlly annoying, but tomie constantly makes loud wailing from your own perspective when not midphase and could cause you to miss important sounds while charging phase/right after a phase

Ich bin nachwievor bärisch bei Novo Nordisk! Die bekommen jetzt auch noch Probleme mit ihrer R&D: "...Novo Nordisk has reported the mixed midphase results behind its push to enter a heart disease market served by Alnylam, BridgeBio and Pfizer..."

The Moment We All Brace Dr. Christina Coughlin confirmed what the close watchers already sensed #AVCT’s Therapeutics Division will present its published data from the first ever dual payload pre|CISION peptide drug conjugate system, fresh from the AACR–NCI–EORTC Molecular Targets Congress in Boston. The meeting itself is jointly organised by three of the field’s most powerful scientific bodies: • #AACR the American Association for Cancer Research • #NCI the National Cancer Institute, the U.S. government’s flagship cancer research arm • #EORTC the European Organisation for Research and Treatment of Cancer Curators of the Molecular Targets meeting; where biotech and pharma unveil the preclinical and translational breakthroughs that shape the next generation of cancer drugs. But unlike #ESMO or #ASCO (equal parts medicine and market theatre) AACR–NCI–EORTC is a laboratory with microphones, where mechanistic data meets interrogation from the same minds who advise the FDA and sit on Big Pharma diligence committees. It’s an entry into the scientific bloodstream; the Sloan Kettering, MD Anderson, and Dana Farber circuit that decides how oncology moves. It’s where principal investigators overlap with FDA advisers, trial architects double as pharma scouts, and every data slide becomes a pipeline discussion. These are the institutions that design early trials. Their clinicians chair ODAC panels, sit on programme boards, and hold advisory roles across AstraZeneca, BMS, Novartis, and Merck’s translational units. When your molecule is dissected in that room, you’re briefing the people shaping tomorrow’s oncology era, a validation level small cap biotechs rarely touch, and scientific acknowledgement from the gatekeepers of both regulation and capital. History leaves a trail: • When ImmunoGen first revealed its ADC linker chemistry here, Roche and Sanofi began the exchanges that would lead to billion dollar licensing, ultimately a $10B AbbVie acquisition. • Alnylam used this same stage to prove its RNAi engine could adapt across diseases, the turning point that transformed RNA therapeutics and built a $25B franchise. • And long before Moderna was a household name, its early mRNA delivery data debuted here, sparking the partnerships that later built a $100B biotech empire. So when Avacta’s dual payload preCISION data appears on this stage, it’s an invitation into the professional conversation that decides what becomes the next oncology backbone. Most companies reach this level of peer review only once their pivotal trials are nearly complete and replication is already baked in. #AVCT, by contrast, arrives midPhase 1b with human safety, tolerability, and efficacy already in hand and knows exactly what it’s holding. The data that has NCI collaborations and pharma’s business development teams waiting for permission to pounce. It’s rare air for a company of Avacta’s size. At this tier, small caps usually attend and leave presenting to the giants. Yet preCISION now sits alongside ADCs, radioligands, and other flagship modalities, the shift from promising chemistry to platform of record. Behold the rerate taking shape. And unlike the figures above, Avacta’s ceiling sits somewhere north of that..🚀

i use envious and moa midphase swap rewind bns/honing for dmg

MIDPHASE HEAVY AMMO GEN PRIMARY TECH

Teaching the Course ‘Midphase’ this year to candidates: “Meant to identify a series of relatively objective features characteristic of an analytic process that has evolved into the midphase. They should each be easily identifiable and describable by both supervisor and candidate”

$PMVP PMV plots ovarian cancer filing after seeing midphase data fiercebiotech.com/biotech/pm…

Terns Pharmaceuticals planning to stop investing in metabolic disease clinical development by year-end, starting a countdown to potential deals for assets including a midphase oral obesity prospect! $TERN #biotech #obesity fiercebiotech.com/biotech/te…

Terns Pharmaceuticals is planning to stop investing in metabolic disease clinical development by year-end, starting a countdown to potential deals for assets including a midphase oral obesity prospect. $TERN fiercebiotech.com/biotech/te…

Bolt famously had slow starts and made it up from 40-75m. Watch bolts races , he was always struggling off the block but he’d turn into a machine in the midphase and even drop off at the end.

As i said, they don sell these kinda chickens anymoree... its the ancient midphase of dinos and chickens

$MKKGY - Merck KGaA fails midphase lupus trial, says totality of data support further development - fiercebiotech.com/biotech/me…